Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9


Beneficial and Adverse Effects of an LXR Agonist on Human Lipid and Lipoprotein Metabolism and Circulating Neutrophils.

Kirchgessner TG, Sleph P, Ostrowski J, Lupisella J, Ryan CS, Liu X, Fernando G, Grimm D, Shipkova P, Zhang R, Garcia R, Zhu J, He A, Malone H, Martin R, Behnia K, Wang Z, Barrett YC, Garmise RJ, Yuan L, Zhang J, Gandhi MD, Wastall P, Li T, Du S, Salvador L, Mohan R, Cantor GH, Kick E, Lee J, Frost RJ.

Cell Metab. 2016 Aug 9;24(2):223-33. doi: 10.1016/j.cmet.2016.07.016.


Safety, pharmacokinetics, and pharmacodynamics of PD 0348292, an oral, direct factor Xa inhibitor, after single and multiple dosings in healthy subjects.

Xuan D, McBride S, Wastall P, Porcari A, DiCarlo L, Boyd RA.

Clin Pharmacol Drug Dev. 2016 Jan;5(1):13-26. doi: 10.1002/cpdd.232. Epub 2015 Nov 5.


Assessment of drug-drug interactions between daclatasvir and methadone or buprenorphine-naloxone.

Garimella T, Wang R, Luo WL, Wastall P, Kandoussi H, DeMicco M, Bruce RD, Hwang C, Bertz R, Bifano M.

Antimicrob Agents Chemother. 2015 Sep;59(9):5503-10. doi: 10.1128/AAC.00478-15. Epub 2015 Jun 29.


Evaluation of drug-drug interaction between daclatasvir and methadone or buprenorphine/naloxone.

Garimella T, Wang R, Luo WL, Wastall P, Kandoussi H, Demicco M, Bruce D, Hwang C, Bertz R, Bifano M.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19628. doi: 10.7448/IAS.17.4.19628. eCollection 2014.


A randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects.

Barrett YC, Wang J, Song Y, Pursley J, Wastall P, Wright R, Lacreta F, Frost C.

Thromb Haemost. 2012 May;107(5):916-24. doi: 10.1160/TH11-09-0634. Epub 2012 Mar 8.


Comparative human pharmacokinetics and metabolism of single-dose oral and intravenous sildenafil.

Muirhead GJ, Rance DJ, Walker DK, Wastall P.

Br J Clin Pharmacol. 2002;53 Suppl 1:13S-20S.


Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man.

Walker DK, Ackland MJ, James GC, Muirhead GJ, Rance DJ, Wastall P, Wright PA.

Xenobiotica. 1999 Mar;29(3):297-310.


The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data.

Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre F, Rance DJ, Wastall P.

J Pharmacol Exp Ther. 1997 Oct;283(1):46-58.


Modipafant, a new PAF antagonist: pharmacokinetics and disposition in rat, dog and man.

Jezequel SG, Uden S, Wastall P.

Xenobiotica. 1996 Sep;26(9):963-75.


Supplemental Content

Loading ...
Support Center